Antonella Licchetta

Lecce, 73014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.

Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.

Journal: Breast cancer research and treatment

Published: March 26, 2026

Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab-Bevacizumab.

Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab-Bevacizumab.

Journal: Journal of gastrointestinal cancer

Published: December 11, 2025

BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Journal: Journal of clinical medicine

Published: November 12, 2025

Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Journal: Cancers

Published: September 18, 2025

CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter Study.

CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter Study.

Journal: Cancers

Published: August 23, 2025

Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.

Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.

Journal: Cancers

Published: September 13, 2024

Immune system and bone microenvironment: rationale for targeted cancer therapies.

Immune system and bone microenvironment: rationale for targeted cancer therapies.

Journal: Oncotarget

Published: October 09, 2019

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.

Journal: Medicina (Kaunas, Lithuania)

Published: September 15, 2019

Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Journal: Medicina (Kaunas, Lithuania)

Published: September 12, 2019

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.

Journal: Medicina (Kaunas, Lithuania)

Published: September 05, 2019

Immunotherapeutic approaches for hepatocellular carcinoma.

Immunotherapeutic approaches for hepatocellular carcinoma.

Journal: Oncotarget

Published: December 08, 2016

Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.

Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.

Journal: Anti-cancer drugs

Published: August 05, 2015

Showing 1-12 of 20

Last Updated: 09/26/2026